CLOVIS ONCOLOGY INC - NOTE 2.500% 9/1 Institutional Ownership

CUSIP: 189464AB6

13F Institutional Holders and Ownership History from Q3 2015 to Q3 2021

Type / Class
Debt / NOTE 2.500% 9/1
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Investment Quick Answers

What is CUSIP 189464AB6?
CUSIP 189464AB6 identifies 189464AB6 - CLOVIS ONCOLOGY INC - NOTE 2.500% 9/1 in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Institutional Holders of CLOVIS ONCOLOGY INC - NOTE 2.500% 9/1 across Reporting Periods

Period Principal Value Change Price (% of par) (Median) Investors
2021 Q3 $0 $0 -$62,511,922 0
2021 Q2 $64,030,002 $62,511,922 +$5,705,123 99.41% 12
2021 Q1 $58,196,002 $55,031,815 +$621,744 94.48% 10
2020 Q4 $58,704,002 $54,158,199 +$102,225 92.2% 11
2020 Q3 $59,878,268 $54,035,301 +$15,600 92.09% 13
2020 Q2 $59,797,002 $53,678,669 -$30,531,872 90.02% 11
2020 Q1 $93,872,002 $83,726,060 +$902,826 89.09% 13
2019 Q4 $92,871,002 $81,733,673 +$741,182 88.21% 12
2019 Q3 $92,017,002 $79,654,678 -$181,154,892 87.11% 11
2019 Q2 $294,542,079 $262,019,315 +$23,698,044 89.01% 31
2019 Q1 $265,827,002 $247,049,002 -$6,071,460 93.01% 28
2018 Q4 $256,030,002 $223,685,002 +$6,157,406 84.03% 33
2018 Q3 $248,376,002 $233,219,002 -$7,283,974 93.55% 24
2018 Q2 $255,361,002 $275,283,088 +$5,779,210 107.58% 26
2018 Q1 $247,786,002 $288,785,002 -$7,068,157 116.31% 29
2017 Q4 $251,632,005 $339,143,007 -$3,649,740 135.0% 27
2017 Q3 $248,571,009 $384,185,000 -$65,228,584 154.36% 29
2017 Q2 $288,036,008 $487,921,013 +$16,608,987 169.36% 28
2017 Q1 $287,637,006 $371,046,009 +$15,524,636 129.02% 28
2016 Q4 $287,828,000 $296,729,000 +$19,396,726 102.9% 31
2016 Q3 $276,338,000 $262,789,000 +$8,487,241 95.02% 21
2016 Q2 $252,382,000 $183,625,000 -$10,139,649 70.94% 14
2016 Q1 $275,808,000 $187,842,325 -$16,048,327 68.27% 19
2015 Q4 $295,334,000 $258,639,000 -$31,281,590 85.97% 24
2015 Q3 $293,502,000 $488,956,500 +$453,035,500 166.75% 28